ABLIS Stock Overview
A clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Abliva AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.33 |
| 52 Week High | kr0.33 |
| 52 Week Low | kr0.33 |
| Beta | 1.16 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -58.42% |
| 5 Year Change | -85.56% |
| Change since IPO | -93.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABLIS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 0.2% |
| 1Y | n/a | -20.7% | 6.5% |
Return vs Industry: Insufficient data to determine how ABLIS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how ABLIS performed against the UK Market.
Price Volatility
| ABLIS volatility | |
|---|---|
| ABLIS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ABLIS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ABLIS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 7 | Ellen Donnelly | abliva.com |
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children’s Hospital of Philadelphia, and Oroboros Instruments.
Abliva AB (publ) Fundamentals Summary
| ABLIS fundamental statistics | |
|---|---|
| Market cap | kr240.31m |
| Earnings (TTM) | -kr85.26m |
| Revenue (TTM) | kr31.00k |
7,752x
P/S Ratio-2.8x
P/E RatioIs ABLIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABLIS income statement (TTM) | |
|---|---|
| Revenue | kr31.00k |
| Cost of Revenue | kr68.30m |
| Gross Profit | -kr68.27m |
| Other Expenses | kr17.00m |
| Earnings | -kr85.26m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
May 23, 2023
| Earnings per share (EPS) | -0.081 |
| Gross Margin | -220,216.13% |
| Net Profit Margin | -275,038.71% |
| Debt/Equity Ratio | 0% |
How did ABLIS perform over the long term?
See historical performance and comparison